MR Pharma




Mega Lifesciences
Concise Prescribing Info
Reduction in the duration of neutropenia & incidence of febrile neutropenia in patients treated w/ cytotoxic chemotherapy for malignancy (except chronic myeloid leukemia & myelodysplastic syndrome).
Dosage/Direction for Use
SC Adult 6 mg single dose for each cycle approx 24 hr following cytotoxic chemotherapy.
Special Precautions
Permanently discontinue if serious allergic reactions occur. Patients w/ AML, myelodysplastic syndrome, chronic myelogenous leukemia, secondary AML. De novo AML in patients <55 yr w/ cytogenetics t(15; 17). High dose chemotherapy; do not use to increase cytotoxic chemotherapy dose beyond established dosage regimen. Potential higher risk in patients w/ recent history of pulmonary infiltrates or pneumonia. Preliminary signs of adult resp distress syndrome (ARDS); discontinue at the onset of pulmonary signs eg, cough, fever & dyspnea associated w/ radiological signs of pulmonary infiltrates & function deterioration w/ increased neutrophil count. Asymptomatic splenomegaly; splenic rupture; monitor spleen size & consider splenic rupture in patients w/ upper left abdominal or shoulder tip pain. Regularly monitor platelet count & hematocrit. Take special care in administering single or combination chemotherapeutic agents known to cause severe thrombocytopenia. Sickle cell crises; monitor appropriate clinical parameters & lab status, & be attentive to possible association to enlargement & vaso-occlusive crisis in patients w/ sickle cell disease. Discontinue immediately w/ leukocyte counts >50 x 109/L after expected nadir. Blood progenitor cell mobilisation in patients or healthy donors. Needle cover contains natural dry rubber (latex derivative) which may cause allergic reactions. Increased bone marrow hematopoietic activity in response to growth factor therapy may cause transient positive bone imaging findings. Not for patients w/ rare hereditary problems of fructose intolerance. Pregnancy; do not use during lactation. Childn.
Adverse Reactions
Headache; nausea; bone & musculoskeletal pain (myalgia, arthralgia, pain in the extremity, back & neck pain), thrombocytopenia; inj site reaction (including inj site pain). Resp failure or ARDS.
Drug Interactions
May cause potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy; administer approx 24 hr following cytotoxic chemotherapy.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Peg-Alvograstim soln for inj 6 mg/0.6 mL
1's;5 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in